❭ Research by medical division ❭ Laboratory Medicine ❭ Medical Biochemistry ❭ The Tumour Marker Group [Bolstad] ❭

Group members

Trine Bjøro, MD, professor. Group leader.

David Warren, PhD

Nils Bolstad, MD

Sigurd Bøe, PhD

Ragnhild Nome, MD

Johanna Géhin, MD

Rolf Anton Klaasen, MPharm

Åge Winje Brustad, Technician

Ann Magritt Liberg, Technician

 
Page visits: 2100
Scroll to top

Home Medical Biochemistry The Tumour Marker Group [Bolstad]

  • Group members
  • Research projects
  • Publications
  • Funding and collaborations

Recent publications

Brun MK, Bjørlykke KH, Viken MK, Stenvik GE, Klaasen RA, Gehin JE, Warren DJ, Sexton J, Sandanger Ø, Kvien TK, Mørk C, Haavardsholm EA, Jahnsen J, Goll GL, Lie BA, Bolstad N, Jørgensen KK, Syversen SW (2023)
HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases
J Intern Med (in press)
DOI 10.1111/joim.13616, PubMed 36843323

Wiken TH, Høivik ML, Buer L, Warren DJ, Bolstad N, Moum BA, Anisdahl K, Småstuen MC, Medhus AW (2023)
Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring
Scand J Gastroenterol, 1-11 (in press)
DOI 10.1080/00365521.2023.2176252, PubMed 36799155

Jørgensen KK, Høivik ML, Chopra A, Benth JŠ, Ricanek P, Moum PB, Jyssum I, Bolstad N, Warren DJ, Vaage PJT, Munthe PLA, Lundin PKEA, Anisdahl K, Syversen SW, Goll GL, Lund-Johansen F, Medhus AW, Jahnsen PJ (2023)
Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type
Scand J Gastroenterol, 1-9 (in press)
DOI 10.1080/00365521.2023.2177884, PubMed 36788656

More publications

Oslo University Hospital is a part of Southern and Eastern Norway Regional Health Authority.

Webmaster for research pages: Trond Olav Berg

Email: trond.olav.berg@rr-research.no

Cookie policy

Accessibility statement (in Norwegian)